U.S. Next Generation Sequencing Market To Reach $16.75 Billion By 2033

September 2025 | Report Format: Electronic (PDF)

U.S. Next Generation Sequencing Market Growth & Trends

The U.S. next generation sequencing market size is anticipated to reach USD 16.75 billion by 2033, expanding at a CAGR of 18.1% from 2025 to 2033, according to a new report by Grand View Research, Inc. Increasing applications of next generation sequencing (NGS) in drug discovery, diagnostics, and personalized medicine, as well as the growing prevalence of cancer and other genetic disorders. In addition, rising cardiovascular diseases is another factor driving the U.S. market’s growth.

According to Centers for Disease Control and Prevention (CDC), heart disease remains the leading cause of death across various demographics in the U.S., including men, women, and individuals of most racial and ethnic backgrounds. On average, a person dies of cardiovascular disease every 33 seconds in the U.S. Sequencing can be employed in cardiovascular genetics to identify genetic risk factors for conditions like familial hypercholesterolemia, cardiomyopathies, and arrhythmias. It enables early detection of individuals at risk and facilitates personalized treatment plans.

Continuous innovations and improvements in NGS technologies, such as sequencing platforms, bioinformatics tools, and sample preparation methods, drive market growth. Enhanced sequencing speed, accuracy, and cost-effectiveness make NGS more accessible and applicable across diverse research and clinical applications. The expanding utility of sequencing techniques in clinical diagnostics, including oncology, rare diseases, genetic disorders, and infectious diseases, is a significant driver of market growth. NGS enables precise and comprehensive genetic analysis, leading to improved diagnosis, treatment selection, and patient care.

The COVID-19 pandemic has significantly affected the U.S. NGS market. As healthcare providers focus on managing the pandemic, routine medical procedures, including genetic testing, have been postponed or canceled. This has caused a decline in the demand for NGS tests in the country. However, the pandemic has also highlighted the importance of genetic testing and its potential in managing and treating diseases. As a result, there has been a renewed interest in NGS-based research and development, which is expected to drive the market’s growth in the coming years. Furthermore, the increased demand for COVID-19 testing has led to the development of new NGS-based diagnostic tests. These tests are expected to play a crucial role in the early detection and management of the disease.

The U.S. NGS market’s growth is driven by the substantial cost associated with NGS technologies. The initial investment in sequencing instruments, reagents, and infrastructure can be prohibitively high for many research laboratories, academic institutions, and smaller healthcare facilities. Additionally, the ongoing operational expenses and maintenance costs further strain limited budgets, hindering access to NGS technology. Sequencing generates vast amounts of complex data, posing significant challenges in storage, analysis, and interpretation. Managing terabytes to petabytes of sequencing data requires robust computational resources and sophisticated bioinformatics tools. Moreover, ensuring data integrity, security, and compliance with privacy regulations adds another layer of complexity to NGS data management.

key Request a free sample copy or view report summary: U.S. Next Generation Sequencing Market Report

U.S. Next Generation Sequencing Market Report Highlights

The consumables segment held the largest market share of 75.40% in 2024. This segment's larger share and exponential growth rate are mainly attributed to its recurrent usage and high demand in NGS commercial and research applications.
The targeted sequencing and resequencing segment held the largest market share of 48.83% in 2024.
The oncology segment accounted for the largest market share of 31.62% in 2024, driven by the rising prevalence of cancer and the increasing adoption of advanced technologies to support precision medicine.
The sequencing segment held the largest market share of 78.27% in 2024. NGS sequencing is the most important phase of the workflow and consequently accounts for the largest share of the market.
The academic research segment held the highest market share of 35.99% in 2024.

U.S. Next Generation Sequencing Market Segmentation

Grand View Research has segmented the U.S. next generation sequencing market on the basis of technology, product, application, workflow, and end use:

U.S. Next Generation Sequencing Technology Outlook (Revenue, USD Million, 2021 - 2033)

Whole Genome Sequencing
Whole Exome Sequencing
Targeted Sequencing & Resequencing
- DNA-based
- RNA-based
Others

U.S. Next Generation Sequencing Product Outlook (Revenue, USD Million, 2021 - 2033)

Platforms
- Sequencing
- Data Analysis
Consumables
- Sample Preparation
- Target Enrichment
- Others

U.S. Next Generation Sequencing Application Outlook (Revenue, USD Million; 2021 - 2033)

Oncology
- Diagnostics and Screening
  - Oncology Screening
    - Sporadic Cancer
    - Inherited Cancer
  - Companion Diagnostics
  - Other Diagnostics
- Research Studies
Clinical Investigation
- Infectious Diseases
- Inherited Diseases
- Idiopathic Diseases
- Non-Communicable/Other Diseases
Reproductive Health
- NIPT
  - Aneuploidy
  - Microdeletions
- PGT
- Newborn Genetic Screening
- Single Gene Analysis
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Consumer Genomics

U.S. Next Generation Sequencing Workflow Outlook (Revenue, USD Million, 2021 - 2033)

Pre-Sequencing
- Nucleic Acid Extraction
- Library Preparation
Sequencing
NGS Data Analysis
- NGS Primary Data Analysis
- NGS Secondary Data Analysis
- NGS Tertiary Data Analysis